Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Falls Church, Virginia Clinical Trials

A listing of Falls Church, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (205) clinical trials

A Phase 1 Study of TSR-022 an Anti-TIM-3 Monoclonal Antibody in Patients With Advanced Solid Tumors (AMBER)

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-TIM-3 (T cell immunoglobulin and mucin containing protein-3) antibody TSR-022, as a monotherapy and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors. The study will be conducted in 2 parts: dose escalation and cohort expansion.

Phase

5.27 miles

Learn More »

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

This is a multicenter, open-label, phase 1 study that is being done to test intratumoral injections of TTI-621 in patients that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts: Dose Escalation and Dose Expansion. During the escalation part ...

Phase

5.27 miles

Learn More »

A Study Evaluating the Safety Pharmacokinetics (PK) and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in subjects with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.

Phase

5.27 miles

Learn More »

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed. During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based upon the following cancer diagnosis: Non-small cell ...

Phase

5.27 miles

Learn More »

A Multiple-dose Study of ASP8374 an Immune Checkpoint Inhibitor as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

This is a multi-center, multiple-dose, dose-escalation and expansion study of ASP8374 as a single agent and in combination with pembrolizumab. After discontinuation of study drug treatment, all participants will complete an end of treatment visit and safety follow-up visits. Participants will be enrolled in respectively escalation cohorts or expansion cohorts. ...

Phase

5.27 miles

Learn More »

A Study of ASP1948 Targeting an Immune Modulatory Receptor in Subjects With Advanced Solid Tumors

This is a dose-escalation and expansion study of ASP1948 as a single agent and in combination with nivolumab. The study consists of 3 periods for monotherapy and combination therapy: screening, treatment and follow up, followed by an optional Re-treatment period for participants that qualify. The escalation cohorts will evaluate escalating ...

Phase

5.27 miles

Learn More »

AO-176 in Multiple Solid Tumor Malignancies

This study will examine AO-176 monotherapy in patients with select advanced solid tumors for which standard therapy proven to provide clinical benefit does not exist or is no longer effective. The study utilizes a classic 3+3 design, with enrollment of 3 patients per cohort and expansion of the cohort in ...

Phase

5.27 miles

Learn More »

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies

Dose escalation of the following will be assessed: escalating doses of AB928 in combination with pegylated liposomal doxorubicin (PLD) at standard doses in participants with advanced metastatic triple-negative breast cancer or ovarian cancer; escalating doses of IPI-549 in combination with the recommended phase 2 dose (RP2D) of AB928 and PLD ...

Phase

5.27 miles

Learn More »

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Dose escalation of AB928 in combination with mFOLFOX at standard doses will be assessed in participants with advanced metastatic GEC or CRC. In this dose escalation combination study participants will receive oral administration of AB928 as well as iv infusion of mFOLFOX. Dose expansion of AB928 in combination with mFOLFOX ...

Phase

5.27 miles

Learn More »

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

This is a multi-center study of XMT-1536 in patients with tumors likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and non-small cell lung cancer, adenocarcinoma subtype. XMT-1536 will be administered as an intravenous infusion once every four weeks. The study consists of two segments: dose escalation (DES) ...

Phase

5.27 miles

Learn More »